Shares of Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) have been given an average rating of “Hold” by the ten brokerages that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and two have given a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $48.03.
TRHC has been the topic of a number of recent analyst reports. Robert W. Baird initiated coverage on shares of Tabula Rasa HealthCare in a research report on Thursday, May 27th. They set an “outperform” rating and a $53.00 price target on the stock. Zacks Investment Research downgraded shares of Tabula Rasa HealthCare from a “hold” rating to a “sell” rating in a research report on Tuesday, August 10th. Finally, Royal Bank of Canada set a $48.26 price objective on shares of Tabula Rasa HealthCare in a research note on Monday, July 12th.
NASDAQ:TRHC traded up $1.70 during mid-day trading on Friday, hitting $30.53. The stock had a trading volume of 5,133 shares, compared to its average volume of 310,757. The stock has a market capitalization of $758.46 million, a price-to-earnings ratio of -7.41 and a beta of 0.90. The company has a 50 day simple moving average of $37.05 and a 200-day simple moving average of $41.81. Tabula Rasa HealthCare has a 52 week low of $27.01 and a 52 week high of $69.31. The company has a current ratio of 1.37, a quick ratio of 1.29 and a debt-to-equity ratio of 4.50.
In other Tabula Rasa HealthCare news, President Orsula V. Knowlton sold 10,000 shares of the business’s stock in a transaction dated Wednesday, July 14th. The stock was sold at an average price of $46.82, for a total value of $468,200.00. Following the transaction, the president now owns 829,360 shares in the company, valued at $38,830,635.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Michael Greenhalgh sold 2,352 shares of the business’s stock in a transaction that occurred on Thursday, August 5th. The shares were sold at an average price of $38.08, for a total value of $89,564.16. Following the completion of the sale, the chief operating officer now directly owns 166,419 shares of the company’s stock, valued at approximately $6,337,235.52. The disclosure for this sale can be found here. Insiders sold 15,352 shares of company stock valued at $707,764 over the last three months. 10.20% of the stock is owned by insiders.
Hedge funds have recently bought and sold shares of the business. Eaton Vance Management bought a new stake in Tabula Rasa HealthCare in the first quarter worth approximately $31,000. FORA Capital LLC bought a new stake in Tabula Rasa HealthCare in the second quarter worth approximately $40,000. PNC Financial Services Group Inc. grew its position in Tabula Rasa HealthCare by 54.2% in the second quarter. PNC Financial Services Group Inc. now owns 1,315 shares of the company’s stock worth $66,000 after acquiring an additional 462 shares in the last quarter. Nisa Investment Advisors LLC bought a new stake in Tabula Rasa HealthCare in the second quarter worth approximately $85,000. Finally, Alpha Paradigm Partners LLC bought a new stake in Tabula Rasa HealthCare in the first quarter worth approximately $134,000. 89.20% of the stock is owned by institutional investors.
About Tabula Rasa HealthCare
Tabula Rasa Healthcare, Inc is a healthcare technology company, which engages in the development of solutions designed for pharmacists, providers, and patients to optimize medication regimens. It operates through the following segments: CareVention HealthCare and MedWise HealthCare. The CareVention HealthCare segment provides services, PACE, which is a center for Medicare & Medicaid services, or CMS, sponsored program providing medical and social services.
See Also: Cash Flow
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.